IN2015DN02335A - - Google Patents

Info

Publication number
IN2015DN02335A
IN2015DN02335A IN2335DEN2015A IN2015DN02335A IN 2015DN02335 A IN2015DN02335 A IN 2015DN02335A IN 2335DEN2015 A IN2335DEN2015 A IN 2335DEN2015A IN 2015DN02335 A IN2015DN02335 A IN 2015DN02335A
Authority
IN
India
Prior art keywords
relates
present
mva
virus
mva virus
Prior art date
Application number
Other languages
English (en)
Inventor
Jordan Ingo
Sandig Volker
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiogen Ag filed Critical Probiogen Ag
Publication of IN2015DN02335A publication Critical patent/IN2015DN02335A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24061Methods of inactivation or attenuation
    • C12N2710/24064Methods of inactivation or attenuation by serial passage
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2335DEN2015 2012-09-28 2012-09-28 IN2015DN02335A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/069256 WO2014048500A1 (en) 2012-09-28 2012-09-28 Novel mva virus and uses thereof

Publications (1)

Publication Number Publication Date
IN2015DN02335A true IN2015DN02335A (es) 2015-08-28

Family

ID=46982581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2335DEN2015 IN2015DN02335A (es) 2012-09-28 2012-09-28

Country Status (12)

Country Link
US (1) US9732325B2 (es)
EP (1) EP2900810B1 (es)
JP (1) JP2015535687A (es)
CN (1) CN104812894B (es)
AU (1) AU2012391162A1 (es)
BR (1) BR112015006798A2 (es)
CA (1) CA2885240A1 (es)
DK (1) DK2900810T3 (es)
IN (1) IN2015DN02335A (es)
MX (1) MX2015003687A (es)
RU (1) RU2015115898A (es)
WO (1) WO2014048500A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018153460A1 (en) * 2017-02-23 2018-08-30 Probiogen Ag Novel vaccinia virus vectors related to mva with extensive genomic symmetries
CN108371715A (zh) * 2018-01-03 2018-08-07 肖小林 一种病毒的靶向性防治药物
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
CA3104392A1 (en) 2018-07-04 2020-01-09 Probiogen Ag Method for purifying an enveloped virus
WO2023128672A1 (ko) * 2021-12-29 2023-07-06 재단법인 아산사회복지재단 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주
WO2023223183A1 (en) 2022-05-16 2023-11-23 Crispr Therapeutics Ag Picornaviral vectors for gene editing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
JP5052893B2 (ja) 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位

Also Published As

Publication number Publication date
CN104812894B (zh) 2021-10-22
WO2014048500A1 (en) 2014-04-03
RU2015115898A (ru) 2016-11-20
US9732325B2 (en) 2017-08-15
JP2015535687A (ja) 2015-12-17
BR112015006798A2 (pt) 2017-11-21
US20150299666A1 (en) 2015-10-22
DK2900810T3 (en) 2019-04-29
EP2900810B1 (en) 2019-02-20
AU2012391162A1 (en) 2015-04-09
CN104812894A (zh) 2015-07-29
EP2900810A1 (en) 2015-08-05
CA2885240A1 (en) 2014-04-03
MX2015003687A (es) 2015-06-15

Similar Documents

Publication Publication Date Title
PH12015501354A1 (en) Antiviral compounds
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
MX2020011767A (es) Vacunas individualizadas para el cancer.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
IN2015DN02335A (es)
MX353827B (es) Formas de rifaximina y usos de la misma.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MX349119B (es) Vacuna de virus de dengue inactivado.
MX347882B (es) Procedimiento mejorado para preparar (3e, 7e)-homofarnesol.
MY191539A (en) Streptococcal vaccine
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
GB201017519D0 (en) Vaccines
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
WO2012047267A3 (en) Polyvalent immunogen
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
BR112015025697A2 (pt) cepa do vírus vaccinia mutante, uso da cepa do vírus vaccinia mutante, método para a produção de um produto de gene recombinante e produto de gene recombinante
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
PH12014501313A1 (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
MX350718B (es) Vacuna de rinitis equina.
WO2013083753A3 (en) Identification of a swine parecho-like virus and applications